MicrobiologybioRxivPreprint
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
DOI 10.1101/2022.03.28.486075
Author
K. K. Chan
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2022 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 32 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship5 papers
Recent·Most cited
- BiophysicsbioRxiv
Machine learning guided design of high affinity ACE2 decoys for SARS-CoV-2 neutralization
M. Chan, K. K. Chan, E. Procko, D. Shukla
The paper uses machine learning to design high-affinity ACE2 decoys for SARS-CoV-2 neutralization, identifying double mutants with binding affinity comparable to a previously known triple mutant.
DOI 10.1021/acs.jpcb.3c00469 - Pharmacology & ToxicologybioRxiv
Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants
L. Zhang, S. Dutta, S. Xiong…·A. B. Malik
This study shows an engineered ACE2 peptide effectively mitigates ARDS and death in mice infected with multiple SARS-CoV-2 variants.
DOI 10.1038/s41589-021-00965-6 - ImmunologybioRxivPreprint
Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
R. Wang, A. Singaraju, K. E. Marks…·D. A. Rao
This study identifies a distinct CD38hi cytotoxic CD8 T cell subset in ICI-induced arthritis, showing clonal expansion and IFN-driven activation.
DOI 10.1101/2021.10.19.464961 - BiochemistrybioRxiv
An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
K. K. Chan, T. J. Tan, K. K. Narayanan, E. Procko
The paper tests an engineered decoy receptor's ability to bind SARS-CoV-2 variants and finds it remains effective against emerging mutations.
DOI 10.1126/sciadv.abf1738